Stimulant Use Disorders: Cocaine, Methamphetamine, and Prescription Stimulants

Introduction

Stimulant use disorders — encompassing cocaine, methamphetamine, and prescription stimulant misuse — share common neurobiological mechanisms while differing in important ways in their pharmacology, health consequences, and treatment. Stimulants are the second most commonly used illicit drug class after cannabis, and stimulant-related overdose deaths have increased dramatically in recent years, driven by the contamination of the stimulant supply with fentanyl.

Key Definitions

Stimulants: A class of substances that increase activity in the central nervous system, producing increased alertness, energy, and euphoria. Include cocaine, amphetamines, methamphetamine, and prescription stimulants (Adderall, Ritalin).

Monoamine transporters: Proteins that remove dopamine, norepinephrine, and serotonin from the synapse. The primary targets of stimulants.

Stimulant psychosis: A psychiatric syndrome resembling paranoid schizophrenia that can occur with heavy stimulant use or withdrawal. Characterized by paranoia, hallucinations, and delusions.

Crash: The period of fatigue, depression, and hypersomnia that follows a stimulant binge, reflecting dopamine depletion.

Binge use: A pattern of stimulant use characterized by continuous use over hours to days, followed by a crash. Common with cocaine and methamphetamine.

Shared Mechanisms of Stimulant Addiction

All stimulants produce their effects by increasing monoamine neurotransmitter levels — primarily dopamine, but also norepinephrine and serotonin — in the brain. They do this through two main mechanisms:

Reuptake inhibition: Blocking the transporters that remove monoamines from the synapse, causing them to accumulate. Cocaine primarily works through this mechanism.

Reverse transport: Causing monoamine transporters to run in reverse, pumping monoamines out of neurons into the synapse. Amphetamines and methamphetamine primarily work through this mechanism, producing larger and more sustained monoamine increases than reuptake inhibitors.

The massive dopamine increase produced by stimulants in the nucleus accumbens drives the intense euphoria of stimulant intoxication and the powerful reinforcement of stimulant use. With chronic use, the dopamine system downregulates — reducing D2 receptor density and dopamine release — producing tolerance and the anhedonia of withdrawal.

Differences Between Stimulants

Cocaine: Short-acting (30-60 minutes), primarily a reuptake inhibitor. Produces intense but brief euphoria, driving binge use. Significant cardiovascular risks. Not directly neurotoxic to dopamine neurons.

Methamphetamine: Longer-acting (8-12 hours), primarily a reverse transporter. Produces more sustained euphoria. Directly neurotoxic to dopamine and serotonin neurons. More severe and prolonged withdrawal. More severe cognitive impairment.

Prescription stimulants (amphetamine, methylphenidate): Therapeutic doses produce much smaller dopamine increases than illicit stimulants, with slower onset. Misuse — particularly at high doses or by non-oral routes — produces effects more similar to illicit stimulants.

Health Consequences

Cardiovascular: All stimulants increase heart rate and blood pressure, increasing the risk of heart attack, stroke, and arrhythmia. Cocaine is particularly associated with coronary artery spasm and acute cardiovascular events. Methamphetamine is associated with cardiomyopathy with chronic use.

Neurological: Stimulants increase stroke risk through hypertension and vasospasm. Methamphetamine produces direct neurotoxicity. All stimulants can cause seizures at high doses.

Psychiatric: Stimulant psychosis — paranoia, hallucinations, delusions — can occur with heavy use or during withdrawal. It typically resolves with abstinence but can persist for weeks to months. Stimulant use is associated with depression, anxiety, and suicidal ideation.

Physical: Weight loss, malnutrition, dental decay (particularly with methamphetamine), skin sores (from compulsive picking), and accelerated aging are common with chronic stimulant use.

Stimulant Withdrawal

Stimulant withdrawal is not medically dangerous but is psychologically challenging:

Acute phase (days 1-7): Extreme fatigue, hypersomnia, increased appetite, depression, and intense craving. The "crash" reflects dopamine depletion.

Subacute phase (weeks 1-4): Continued depression, anhedonia, and craving. Sleep disturbances are common.

Protracted phase (months): Episodic craving, particularly in response to drug-related cues. Anhedonia may persist for months, reflecting the slow recovery of the dopamine system.

Treatment

No FDA-approved medications exist for stimulant use disorders. Treatment relies primarily on behavioral therapies:

Contingency Management (CM): The most evidence-based treatment for stimulant use disorders. Uses positive reinforcement to reward abstinence. The NIDA Clinical Trials Network has demonstrated CM's efficacy across multiple stimulant use disorders.

Cognitive Behavioral Therapy (CBT): Addresses the thoughts, behaviors, and triggers that contribute to stimulant use. Particularly effective for cocaine use disorder.

The Matrix Model: A comprehensive outpatient treatment program developed specifically for stimulant use disorders, combining CBT, family education, 12-step facilitation, and drug testing.

Emerging medications: Naltrexone + bupropion has shown efficacy for methamphetamine use disorder. Research is ongoing into medications for cocaine use disorder including NAC, modafinil, and a cocaine vaccine.

Frequently Asked Questions

Why is stimulant withdrawal so depressing?
Stimulant withdrawal produces profound depression and anhedonia because the dopamine system — which is responsible for motivation and the ability to feel pleasure — has been depleted and downregulated by chronic stimulant use. The brain's reward system has been recalibrated around the stimulant, and without it, natural rewards feel flat and meaningless. This anhedonia gradually resolves as the dopamine system recovers with sustained abstinence.

Can stimulant use disorder be treated with medication?
Currently, no medications are FDA-approved for stimulant use disorders. However, the naltrexone + bupropion combination has shown significant efficacy for methamphetamine use disorder in a Phase 3 trial and may eventually receive FDA approval. Research into medications for cocaine use disorder is ongoing.

Key Takeaways

• Stimulant use disorders share common neurobiological mechanisms — massive dopamine release followed by dopamine system downregulation — while differing in pharmacology and health consequences.
• Methamphetamine is directly neurotoxic to dopamine neurons; cocaine is not, but produces significant neuroadaptation.
• Stimulant withdrawal is characterized by profound depression and anhedonia reflecting dopamine depletion.
• Contingency management is the most evidence-based treatment for stimulant use disorders.
• The naltrexone + bupropion combination represents a major advance in pharmacological treatment for methamphetamine use disorder.

Additional Resources

Related articles on Sobriety Navigator: Cocaine Use Disorder, Methamphetamine Addiction, Dopamine and Reward Pathways, Contingency Management.